Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy

Cardiovascular Journal of Africa

Volumn 22, Issue 1, 2011, Pages 38-44

  Morrissey, Ryan P ^a   Philip, Kiran J ^a   Schwarz, Ernst R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anderson Fabry; Cardiac MRI (CMR); Fabry's; Late delayed gadolinium enhancement; Left ventricular hypertrophy; Restrictive cardiomyopathy; Tissue doppler imaging

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA GALACTOSIDASE; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; NITRATE; AGALSIDASE ALFA; AGALSIDASE BETA; DIURETIC AGENT; PLACEBO;

ANGINA PECTORIS; AORTA VALVE DISEASE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; MITRAL VALVE DISEASE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TISSUE DOPPLER IMAGING; VEIN GRAFT; ALPHA GALACTOSIDASE DEFICIENCY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DIASTOLIC DYSFUNCTION; ELECTROCARDIOGRAM; ENZYME DEFICIENCY; GENETIC VARIABILITY; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HYPERTROPHIC CARDIOMYOPATHY; MITRAL VALVE REGURGITATION; PHASE 2 CLINICAL TRIAL (TOPIC); SEX DIFFERENCE;

ADULT; AGE FACTORS; ARRHYTHMIAS, CARDIAC; CARDIOMEGALY; CARDIOMYOPATHIES; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART DISEASES; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 79951595694     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Phillips JA, Kniffin CL, Kelly J, et al. #301500 Fabry Disease. OMIM. Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=301500. Accessed on: February 19, 2009.
2. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372: 1427-1435.
3. Anderson W. A case of 'angeiokeratoma'. Br J Dermatol 1898; 10: 113-117.
4. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syph 1898; 43: 187-200.
5. Sweeley CC, Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963; 238: 3148-3150.
6. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-1167.
7. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. New Eng J Med 1995; 333: 288-293.
8. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40. (Pubitemid 43927374)
9. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009. Available at: http://ndt.oxfordjournals.org/cgi/content/full/gfp031v2. Last accessed on April 14, 2009.
10. Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007; 30: 68-78. (Pubitemid 46140228)
11. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347-352.
12. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007; 9: 34-45. (Pubitemid 46115959)
13. Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol 2007; 24: 15-25. (Pubitemid 47576679)
14. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-760. (Pubitemid 33032930)
15. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775. (Pubitemid 33032933)
16. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-242. (Pubitemid 38406640)
17. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-346. (Pubitemid 36205932)
18. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008; 130: 367-373.
19. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107: 1978-1984. (Pubitemid 36506070)
20. Hughes SE, McKenna WJ. New insights into the pathology of inherited cardiomyopathy. Heart 2005; 91: 257-264.
21. Stöllberger C, Finsterer J. Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy. Clin Cardiol 2007; 30: 375-380. (Pubitemid 47312887)
22. Wood MJ, Picard MH. Utility of echocardiography in the evaluation of individuals with cardiomyopathy. Heart 2004; 90: 707-712. (Pubitemid 38668557)
23. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139: 1101-1108. (Pubitemid 30390343)
24. Linhart A, Lubanda JC, Palecek T, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001; 24: 75-83. (Pubitemid 33061636)
25. Elleder M, Bradová V, Smíd F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990; 417: 449-455. (Pubitemid 20345820)
26. Ogawa K, Sugamata K, Funamoto N, et al. Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol 1990; 21: 1067-1073. (Pubitemid 20349232)
27. Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002; 70: 994-1002. (Pubitemid 34259315)
28. Sadick N, Thomas L. Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 2007; 16: 200-206. (Pubitemid 46760677)
29. Shah JS, Lee P, Hughes D, et al. The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 2005; 91: 533-534. (Pubitemid 40432794)
30. Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40: 1668-1674. (Pubitemid 35253646)
31. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007; 28: 1228-1235. (Pubitemid 47343855)
32. Pinderski LJ, Strotmann J. Congestive heart failure in Fabry cardiomyopathy: Natural history experience in an international cohort of 1,448 patients. J Heart Lung Transplant 2006; 25: S70.
33. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26: 1221-1227. (Pubitemid 40863129)
34. Utsumi K, Ueda K, Watanabe M, et al. Thrombosis in Japanese patients with Fabry disease. J Neurol Sci 2009. Available at: http://www.jns-journal.com/ article/S0022-510X(09)00413-4/abstract. Last accessed on April 15, 2009.
35. Kovarnik T, Mintz GS, Karetova D, et al. Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. J Inherit Metab Dis 2008; 31: 753-760.
36. Kalliokoski RJ, Kalliokoski KK, Sundell J, et al. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 2005; 28: 563-573. (Pubitemid 40753685)
37. Cortigiani L, Rigo F, Gherardi S, Galderisi M, Sicari R, Picano E. Prognostic implications of coronary flow reserve on left anterior descending coronary artery in hypertrophic cardiomyopathy. Am J Cardiol 2008; 102: 1718-1723.
38. Roudebush CP, Foerster JM, Bing OH. The abbreviated PR interval of Fabry's disease. N Engl J Med 1973; 289: 357-358.
39. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96: 842-846. (Pubitemid 41319722)
40. Weidemann F, Strotmann JM, Niemann M, et al. Heart Valve Involvement in Fabry Cardiomyopathy. Ultrasound Med Biol 2008. Available at: http://www.umbjournal.org/article/S0301-5629(08)00500-0/abstract. Last accessed on April 14, 2009.
41. Hoigné P, Attenhofer Jost CH, Duru F, et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol 2006; 111: 413-422. (Pubitemid 44205296)
42. Toro R, Perez-Isla L, Doxastaquis G, et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009; 132: 38-44.
43. Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006; 47: 1663-1671. (Pubitemid 44313825)
44. Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 51: 2058-2061. (Pubitemid 351680521)
45. Koskenvuo JW, Engblom E, Kantola IM, et al. Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance. Clin Physiol Funct Imaging 2009; 29: 177-180.
46. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107: 1978-1984. (Pubitemid 36506070)
47. Germans T, van Rossum AC. The use of cardiac magnetic resonance imaging to determine the aetiology of left ventricular disease and cardiomyopathy. Heart 2008; 94: 510-518. (Pubitemid 351441415)
48. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24: 2151-2155. (Pubitemid 37486535)
49. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43: 2260-2264. (Pubitemid 38757595)
50. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009; 53: 284-291.
51. Silva C, Moon JC, Elkington AG, John AS, Mohiaddin RH, Pennell DJ. Myocardial late gadolinium enhancement in specific cardiomyopathies by cardiovascular magnetic resonance: a preliminary experience. J Cardiovasc Med (Hagerstown) 2007; 8: 1076-1079. (Pubitemid 351339573)
52. Bohl S, Wassmuth R, Abdel-Aty H, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 2008; 24: 597-607.
53. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26: 1461-1474. (Pubitemid 41373486)
54. Marcu CB, Nijveldt R, Beek AM, Van Rossum AC. Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. Heart Lung Circ 2007; 16: 70-78. (Pubitemid 46421764)
55. Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2006; 48: 2410-2422. (Pubitemid 44881224)
56. Sechtem U, Mahrholdt H, Vogelsberg H. Cardiac magnetic resonance in myocardial disease. Heart 2007; 93: 1520-1527. (Pubitemid 350205539)
57. De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. Am J Roentgenol 2009; 192: W97-102.
58. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 2414-2421. (Pubitemid 351826874)
59. Imbriaco M, Spinelli L, Cuocolo A, et al. MRI characterization of myocardial tissue in patients with Fabry's disease. Am J Roentgenol 2007; 188: 850-853.
60. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-1411. (Pubitemid 34263268)
61. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110: 1047-1053. (Pubitemid 39319001)
62. Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 2399-2403. (Pubitemid 50011583)
63. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16. (Pubitemid 32634266)
64. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86. (Pubitemid 351640010)
65. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc 2001; 285: 2743-2749. (Pubitemid 32525371)
66. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004; 66: 158-165. (Pubitemid 39117524)
67. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006; 97: 1515-1518.
68. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153-158. (Pubitemid 351211719)
69. Kovacevic-Preradovic T, Zuber M, Jost CH, et al. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 2008; 9: 729-735.
70. Koskenvuo JW, Hartiala JJ, Nuutila P, et al. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 2008; 31: 432-441.
71. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119: 524-529.
72. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 2003; 348: 1186-1187. (Pubitemid 36337339)
73. Chimenti C, Morgante E, Tanzilli G, et al. Angina in Fabry disease reflects coronary small vessel disease. Circ Heart Fail 2008; 1: 161-169.
74. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92: 357-360.
75. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. 2009 Appropriateness criteria for coronary revascularization. J Am Coll Cardiol 2009; 53: 530-553.
76. Chimenti C, Morgante E, Critelli G, Russo MA, Frustaci A. Coronary artery bypass grafting for Fabry's disease: veins more suitable than arteries? Hum Pathol 2007; 38: 1864-1867. (Pubitemid 350179937)
77. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 2008; 52(13): e1-142.
78. Choi S, Seo H, Park M, et al. Fabry disease with aortic regurgitation. Ann Thorac Surg 2009; 87: 625-628.
79. Miyata M, Sato T, Iwai-Takano M, Suzuki H, Ishibashi T, Takeishi Y. Mitral valve replacement due to mitral valve regurgitation in patient with Fabry disease. J Card Fail 2008; 14: S151.
80. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol 2008; 51: e1-62.
81. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol 2009; 53: e1-e90.
82. Fukuta H, Little WC. Observational studies of statins in heart failure with preserved systolic function. Heart Fail Clin 2008; 4: 209-216. (Pubitemid 351552052)
83. Magage S, Linhart A, Bultas J, et al. Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography 2005; 22: 333-339. (Pubitemid 40559535)
84. Karras A, De Lentdecker P, Delahousse M, et al. Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era. Am J Transplant 2008; 8: 1345-1348. (Pubitemid 351763696)